

Approved by:



CERTIFICATE

2024

Universitätsklinikum Essen
Institut für Pathologie
Hufelandstr. 55
45147 Essen
Germany

has successfully completed the proficiency test

TERT Mutation Analysis in Glioma, Meningioma and Bladder Carcinoma (MolPath)

Berlin, October 1, 2024

(Trial Period 17.06.2024 - 05.07.2024)

Prof. Dr. med. Claudia Wickenhauser
Quality in Pathology - QuIP GmbH

Prof. Dr. med. Markus J. Riemenschneider
Neuropathologie Universitätsklinikum Regensburg

Lead panel institute of the proficiency test:

Prof. Dr. med. Markus J. Riemenschneider, Neuropathologie, University Hospital Regensburg, Germany

This certificate includes the separate individual evaluation of the test and the corresponding proficiency test report.

This proficiency test was organized by:
Qualitätssicherungs-Initiative Pathologie QuIP GmbH /
Reinhardtstr. 1 / 10117 Berlin / office@quip.eu / www.qualityinpathology.com

